Nevertheless, this limited preliminary data is compelling and suggests that additional work needs to be done to firmly establish FGF19/FGFR4/EpCAM signaling as a biomarker for HCC risk assessment. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.